文献速递核素与放射性配体治疗肿瘤 PET/CT

基于[177Lu]Lu-LNC1011的PSMA靶向放射性配体治疗转移性去势抵抗性前列腺癌:一项先导研究

PSMA-targeted radioligand therapy with [177Lu]Lu-LNC1011 for metastatic castration-resistant prostate cancer: a pilot study.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-04-10

该先导研究纳入8例转移性去势抵抗性前列腺癌患者,每6周静脉给予[177Lu]Lu-LNC1011治疗,最多6个周期。主要副作用为血液学毒性,1例3级贫血、4例2级白细胞减少和血小板减少;全身有效剂量平均0.18 mSv/MBq,肾脏吸收剂量最高(3.11 ± 0.26 mSv/MBq)。全部患者PSA下降超过50%,分子影像完全缓解2例(25%)、部分缓解4例(50%)、疾病进展2例(25%)。

要点

  • 8例mCRPC患者接受[177Lu]Lu-LNC1011治疗,血液学毒性为主要副作用。
  • 全身有效剂量平均0.18 mSv/MBq,肾脏吸收剂量最高(3.11 ± 0.26 mSv/MBq)。
  • 全部患者PSA下降超过50%,分子影像完全缓解2例(25%)、部分缓解4例(50%)。

原文

BACKGROUND: Preclinical studies have shown that the long-acting PSMA-targeting radiopharmaceutical [177Lu]Lu-LNC1011 based on dansylated amino acid modification had high tumor uptake and prolonged retention. This study aimed to explore its safety and efficacy in patients with metastatic castration-resistant prostate cancer (mCRPC). METHODS: Eight mCRPC patients who met the inclusion criteria received intravenous treatment with [177Lu]Lu-LNC1011. Treatment was repeated every 6 weeks for up to a maximum of 6 cycles. Molecular imaging and hematology markers were the main evaluation indicators. The primary endpoints were biochemical (PSA) response and molecular imaging response. Toxicity grading was assessed using the Common Terminology Criteria for Adverse Events version 5.0. RESULTS: Hematological toxicity was the primary side effect. In all patients, adverse events (AEs) after [177Lu]Lu-LNC1011 treatment were primarily characterized by decreased levels of hemoglobin, white blood cells and platelets. Grade 3 anemia was recorded in 1 patient, and grade 2 leukopenia and thrombocytopenia were recorded in 4 patients. The average systemic effective dose was 0.18 mSv/MBq, and the kidney was the organ with the highest absorbed dose (3.11 ± 0.26 mSv/MBq). Long half-life (71.30 ± 8.23 h) and high absorbed dose [5.77, (range 5.5-14 Gy/GBq)] were calculated in the lesions. All patients had a more than 50% decline of PSA during treatment, and one patient dropped to 0 ng/mL. According to assessment criteria adapted from the PERCIST v.1.0 criteria, complete response, partial response, and disease progression were observed in 2 (25%), 4 (50%), and 2 (25%) patients, respectively. CONCLUSION: [177Lu]Lu-LNC1011 was well tolerated and had acceptable side effects for PSMA-targeted radioligand therapy. Tumor lesions received high radiation doses and had excellent responses to the treatment. Dose escalation studies in a larger number of patients are worth pursuing and necessary to confirm these results. URL OF REGISTRY: https://clinicaltrials.gov/study/NCT06809426?term=NCT06809 . TRIAL REGISTRATION: NCT06809426, registration date: 2025-01-23.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Hou L, Wang Y, Fu H, et al. PSMA-targeted radioligand therapy with [177Lu]Lu-LNC1011 for metastatic castration-resistant prostate cancer: a pilot study. Eur J Nucl Med Mol Imaging. 2025. PMID: 40208314. doi:10.1007/s00259-025-07245-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。